The NDA submission follows the successful completion of a pivotal Phase III global clinical trial
A Post Graduate in Science faculty and has a wide experience spanning over 35 years in the field of manufacturing Bulk Drugs and Active Pharmaceutical Intermediaries
The product will be manufactured at Lupin’s Chhatrapati Sambhajinagar facility in India
This milestone marks the first-ever NDA submission to the U.S. FDA for a drug, fully discovered and developed by an Indian pharmaceutical company
Health leaders rally for a national awakening on prevention, mental wellness, and lifestyle reform at ‘Illness to Wellness’ heart care conference
The collaboration is expected to facilitate access to world-class treatments and specialised care for Iraqi personnel
Subscribe To Our Newsletter & Stay Updated